We are live on ! Find out more
SYNB

Putnam BioRevolution ETF

Delisted

SYNB was delisted on the 13th of November, 2025.

5 hedge funds and large institutions have $7.03M invested in Putnam BioRevolution ETF in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more capital invested

Capital invested by funds: $3.64M → $7.03M (+$3.39M)

67% more funds holding

Funds holding: 35 (+2)

10.56% more ownership

Funds ownership: 75.72%86.28% (+11%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
PI
1
Putnam Investments
Massachusetts
$3.64M
GT
2
Glenview Trust
Kentucky
$2.01M +$1.85M +69,185 New
Jane Street
3
Jane Street
New York
$766K +$406K +15,149 +136%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$610K +$558K +20,841 +17,966%
UBS Group
5
UBS Group
Switzerland
$3.26K +$3K +112 New

SYNB Hedge Fund Activity: Q4 2023 in Review

5 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Putnam BioRevolution ETF (SYNB) for Q4 2023, worth a combined $7.03M — up 93% from $3.64M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SYNB positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Glenview Trust, opening a new position worth an estimated $1.85M.

  • 5 institutional investors held Putnam BioRevolution ETF (SYNB) as of Q4 2023, up from 3 in Q3 2023.
  • Funds reported $7.03M of Putnam BioRevolution ETF stock for Q4 2023, up 93% quarter-over-quarter.
  • 2 funds opened new Putnam BioRevolution ETF positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Putnam BioRevolution ETF buyer in Q4 2023 was Glenview Trust, an estimated $1.85M added.

Based on aggregated 13F filings for Q4 2023.